 THE WOODLANDS, Texas, Dec. 11, 2020 GLOBE NEWSWIRE -- Lexicon Pharmaceuticals, Inc. Nasdaq: LXRX today announced that it had entered into a securities purchase agreement with certain institutional investors providing for the purchase and sale, in a registered direct offering, of 20,312,500 shares of its common stock, par value 0.001 the Common Stock, at a price of 3.20 per share, for aggregate gross proceeds to the Company of 65,000,000 before deducting fees to the placement agent and other estimated offering expenses payable by the Company. The transaction is expected to close on December 16, 2020, subject to satisfaction of customary closing conditions. 